AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting

To protect commercial confidentiality the following appraisal will be held in private

5. Appraisal 1: Full Submission (WPAS)
   Sorafenib (Nexavar®) for the treatment of hepatocellular carcinoma
   Enclosure: 2/AWMSG/0316 Appendices

The meeting will now open to the public (approximately 10.30am)

6. Chairman’s report (verbal update)

7. Appraisal 2: Full Submission
   Ulipristal acetate (Esmya®) for the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age
   Enclosure: 3/AWMSG/0316 Appendices

8. Appraisal 3: Limited Submission
   Prucalopride (Resolor®) for the symptomatic treatment of chronic constipation in men in whom laxatives fail to provide adequate relief
   Enclosure: 4/AWMSG/0316 Appendices

Date of next meeting: 20th April 2016 in Cardiff